問卷

TPIDB > Search Result

Search Result

篩選

List

99Cases

2024-09-01 - 2032-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-05-01 - 2030-12-31

Phase III

Not yet recruiting
A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas
  • Condition/Disease

    Extrapulmonary Neuroendocrine Cancer (epNEC)

  • Test Drug

    注射用凍晶粉末 注射用懸液劑 注射用懸液劑

Participate Sites
3Sites

Recruiting2Sites

2024-10-01 - 2029-09-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2024-11-01 - 2029-08-31

Phase III

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-11-01 - 2029-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2024-12-01 - 2031-05-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2024-12-17 - 2030-08-23

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-05-01 - 2028-07-31

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-05-26 - 2031-01-28

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-06-10 - 2033-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites